Results 1 to 10 of about 5,366 (148)

Efficacy and safety of laparoscopic pancreaticoduodenectomy combined with a modified perioperative intraperitoneal chemotherapy regimen in resectable pancreatic head cancer: a dual-center retrospective cohort study [PDF]

Frontiers in Oncology
BackgroundSurgical resection for pancreatic cancer is associated with high rates of locoregional recurrence and peritoneal metastasis, leading to poor prognosis. This study aimed to evaluate the safety and efficacy of laparoscopic pancreaticoduodenectomy
Ang Li, Yu Zhang, Yue Zhang, Jianhua Liu, Feng Feng, Chen Xu, Fengshan Li   +6 more
doaj   +2 more sources

Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer [PDF]

Obstetrics & Gynecology Science, 2021
Objective To investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidation treatment after completing first-line treatment in patients with advanced ovarian cancer.
Jieun Ko, Hyeong In Ha, Min Chul Choi, Sang Geun Jung, Hyun Park, Won Duk Joo, Seung Hun Song, Chan Lee, Joon Mo Lee   +8 more
doaj   +1 more source

Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis

International Journal of Hyperthermia, 2023
Background The original meta-analysis of hyperthermic intraperitoneal chemotherapy (HIPEC) is already outdated, owing to the latest trial results. This study aimed to clarify the efficacy and adverse events of cytoreductive surgery with HIPEC compared to
Yu Xia, He Wang, Jing Zhang, Yongjun Wang   +3 more
doaj   +1 more source

Lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy for T4 gastric cancer patients: A retrospective clinical study

Frontiers in Oncology, 2023
ObjectiveTo explore the clinical efficacy of lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with T4 gastric cancer after surgery and to evaluate its impact on survival.Materials and methodsData on patients ...
Yuxin Zhong, Wenzhe Kang, Haitao Hu, Weikun Li, Jing Zhang, Yantao Tian   +5 more
doaj   +1 more source

Single versus multiple hyperthermic intraperitoneal chemotherapy applications for T4 gastric cancer patients: Efficacy and safety profiles

Frontiers in Oncology, 2023
ObjectiveTo explore the clinical safety and efficacy of single and multiple applications of lobaplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with T4 gastric cancer and to evaluate the impact of HIPEC on peritoneal ...
Jing Zhang, Yuemin Sun, Xiaofeng Bai, Peng Wang, Liang Tian, Yantao Tian, Yuxin Zhong   +6 more
doaj   +1 more source

Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei

Zhongliu Fangzhi Yanjiu, 2020
Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP).
SHI Guanjun, XIA Ao, AN Lubiao, ZHAI Xichao, MA Ruiqing, LU Yiyan, PANG Shaojun, CAI Ying, WANG Bing, CHEN Feng, XU Hongbin   +10 more
doaj   +1 more source

Hyperthermic intraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: a single Chinese center analysis

BMC Surgery, 2022
Purpose About 15%—40% of gastric cancer patients have peritoneal metastasis, which leads to poor prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) is considered to be an effective treatment for these patients. This study evaluated the efficacy
Yunzi Wu, Xiaohao Zheng, Chunyang Sun, Shenghui Wang, Shikang Ding, Ming Wu, Jing Zhang, Bingzhi Wang, Liyan Xue, Lin Yang, Yantao Tian, Yibin Xie   +11 more
doaj   +1 more source

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study

Frontiers in Oncology, 2022
To evaluate the additive effects of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval debulking surgery (IDS) in patients with advanced-stage ovarian cancer.
Yong Jae Lee, Ki Eun Seon, Dae Chul Jung, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim   +7 more
doaj   +1 more source

Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?

Cancer Treatment and Research Communications, 2022
Introduction: The role of a molecular pattern predictive of hyperthermic intraperitoneal chemotherapy (HIPEC) efficacy in advanced ovarian cancer (AOC) patients has been poorly investigated.
Valentina Ghirardi, Francesca De Felice, Marco D'Indinosante, Federica Bernardini, Maria Teresa Giudice, Anna Fagotti, Giovanni Scambia   +6 more
doaj   +1 more source

The efficacy of traditional chinese medicine combined with hyperthermic intraperitoneal chemotherapy for malignant ascites: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Objective: Malignant ascites (MA) is a common complication of terminal cancer, which seriously affects the life quality and prognosis of patients. Both hyperthermic intraperitoneal chemotherapy (HIPEC) and traditional Chinese medicine (TCM) preparations ...
Zhixian Lin, Jiangfeng Chen, Yunxia Liu
doaj   +1 more source